Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Prognosis and Chemosensitivity of Deficient MMR Phenotype in Patients with Metastatic Colorectal Cancer: an AGEO Retrospective Multicenter Study.

Tougeron D, Sueur B, Zaanan A, De La Fouchardiere C, Sefrioui D, Lecomte T, Aparicio T, Guetz GD, Artru P, Hautefeuille V, Coriat R, Moulin V, Locher C, Touchefeu Y, Lecaille C, Goujon G, Ferru A, Evrard C, Chautard R, Gentilhomme L, Vernerey D, Taieb J, André T, Henriques J, Cohen R; Association des Gastro-entérologues oncologues (AGEO).

Int J Cancer. 2020 Jan 22. doi: 10.1002/ijc.32879. [Epub ahead of print]

PMID:
31970760
2.

Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients.

Aparicio T, Henriques J, Manfredi S, Tougeron D, Bouché O, Pezet D, Piessen G, Coriat R, Zaanan A, Legoux JL, Terrebone E, Pocard M, Gornet JM, Lecomte T, Lombard-Bohas C, Perrier H, Lecaille C, Lavau-Denes S, Vernerey D, Afchain P; NADEGE Investigators.

Int J Cancer. 2020 Jan 7. doi: 10.1002/ijc.32860. [Epub ahead of print]

PMID:
31912484
3.

[A diffuse rash].

Vétois D, Lheure C, Rosencher E, Zaanan A, Auclin E, Pouchot J, Lafont E.

Rev Med Interne. 2019 Dec 20. pii: S0248-8663(19)31177-4. doi: 10.1016/j.revmed.2019.11.011. [Epub ahead of print] French. No abstract available.

PMID:
31870651
4.

High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer.

Zaanan A, Calmel C, Henriques J, Svrcek M, Blons H, Desbois-Mouthon C, Merabtene F, Goumard C, Parc Y, Gayet B, Taieb J, Validire P, Louvet C, Fléjou JF, Le Bouc Y, Praz F.

Cell Oncol (Dordr). 2019 Dec 10. doi: 10.1007/s13402-019-00484-6. [Epub ahead of print]

PMID:
31823290
5.

Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.

Moati E, Blons H, Taly V, Garlan F, Wang-Renault SF, Pietrasz D, Didelot A, Garrigou S, Saint A, Pernot S, Taieb J, Laurent-Puig P, Zaanan A.

Int J Cancer. 2019 Aug 31. doi: 10.1002/ijc.32657. [Epub ahead of print]

PMID:
31472013
6.

Exploring the best treatment options for BRAF-mutant metastatic colon cancer.

Taieb J, Lapeyre-Prost A, Laurent Puig P, Zaanan A.

Br J Cancer. 2019 Sep;121(6):434-442. doi: 10.1038/s41416-019-0526-2. Epub 2019 Jul 29. Review.

PMID:
31353365
7.

The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.

Taieb J, Jung A, Sartore-Bianchi A, Peeters M, Seligmann J, Zaanan A, Burdon P, Montagut C, Laurent-Puig P.

Drugs. 2019 Sep;79(13):1375-1394. doi: 10.1007/s40265-019-01165-2. Review.

8.

[Microsatellite instability and cancer: from genomic instability to personalized medicine].

Collura A, Lefevre JH, Svrcek M, Tougeron D, Zaanan A, Duval A.

Med Sci (Paris). 2019 Jun-Jul;35(6-7):535-543. doi: 10.1051/medsci/2019093. Epub 2019 Jul 5. Review. French.

PMID:
31274083
9.

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.

Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, André T.

Ann Oncol. 2019 Sep 1;30(9):1466-1471. doi: 10.1093/annonc/mdz208.

PMID:
31268130
10.

Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients.

de la Fouchardière C, Cohen R, Malka D, Guimbaud R, Bourien H, Lièvre A, Cacheux W, Artru P, François E, Gilabert M, Samalin-Scalzi E, Zaanan A, Hautefeuille V, Rousseau B, Senellart H, Coriat R, Flippot R, Desseigne F, Lardy-Cleaud A, Tougeron D.

Oncologist. 2019 Dec;24(12):e1331-e1340. doi: 10.1634/theoncologist.2018-0914. Epub 2019 May 31.

11.

Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data.

Boulet S, Ursino M, Thall P, Landi B, Lepère C, Pernot S, Burgun A, Taieb J, Zaanan A, Zohar S, Jannot AS.

Stat Methods Med Res. 2019 Apr 9:962280219841082. doi: 10.1177/0962280219841082. [Epub ahead of print]

PMID:
30963815
12.

How to better select patients with advanced gastric cancer for immunotherapy.

Zaanan A, Taieb J.

Transl Gastroenterol Hepatol. 2019 Jan 31;4:6. doi: 10.21037/tgh.2019.01.06. eCollection 2019. No abstract available.

13.

Comparison of three lymph node staging schemes for predicting the outcome in patients with small bowel adenocarcinoma: A population-based cohort and international multicentre cohort study.

Zhou YY, Du XJ, Zhang CH, Aparicio T, Zaanan A, Afchain P, Chen LP, Hu SK, Zhang PC, Wu M, Zhang QW, Wang H.

EBioMedicine. 2019 Mar;41:276-285. doi: 10.1016/j.ebiom.2019.02.043. Epub 2019 Feb 26.

14.

Immunotherapy in advanced gastric cancer, is it the future?

Coutzac C, Pernot S, Chaput N, Zaanan A.

Crit Rev Oncol Hematol. 2019 Jan;133:25-32. doi: 10.1016/j.critrevonc.2018.10.007. Epub 2018 Nov 2. Review.

PMID:
30661655
15.

[Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?]

Zaanan A, Taieb J.

Bull Cancer. 2019 Feb;106(2):129-136. doi: 10.1016/j.bulcan.2018.10.011. Epub 2018 Dec 4. Review. French.

PMID:
30527814
16.

Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study.

Rompteaux P, Gagnière J, Gornet JM, Coriat R, Baumgaertner I, Lecomte T, Afchain P, Zaanan A, Pocard M, Bachet JB, Bonichon-Lamichhane N, Bouché O, Faucheron JL, Forestier J, Lecaille C, Manfredi S, Tougeron D, Terrebonne E, Chehimi M, Villing AL, Sarda C, Legoux JL, Benamouzig R, Aparicio T.

Eur J Surg Oncol. 2019 Mar;45(3):331-335. doi: 10.1016/j.ejso.2018.11.012. Epub 2018 Nov 22.

PMID:
30501999
17.

Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

Zaanan A, Bouché O, Benhaim L, Buecher B, Chapelle N, Dubreuil O, Fares N, Granger V, Lefort C, Gagniere J, Meilleroux J, Baumann AS, Vendrely V, Ducreux M, Michel P; Thésaurus National de Cancérologie Digestive (TNCD).

Dig Liver Dis. 2018 Aug;50(8):768-779. doi: 10.1016/j.dld.2018.04.025. Epub 2018 Jun 6.

PMID:
29886081
18.

Impact of an optimized colonoscopic screening program for patients with Lynch syndrome: 6-year results of a specialized French network.

Perrod G, Samaha E, Rahmi G, Khater S, Abbes L, Savale C, Perkins G, Zaanan A, Chatellier G, Malamut G, Cellier C.

Therap Adv Gastroenterol. 2018 May 27;11:1756284818775058. doi: 10.1177/1756284818775058. eCollection 2018.

19.

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study.

Pernot S, Dubreuil O, Aparicio T, Le Malicot K, Tougeron D, Lepère C, Lecaille C, Marthey L, Palle J, Bachet JB, Zaanan A, Taieb J.

Br J Cancer. 2018 Aug;119(4):424-428. doi: 10.1038/s41416-018-0133-7. Epub 2018 Jun 6.

20.

Colorectal Cancer: Why Does Side Matter?

Gallois C, Pernot S, Zaanan A, Taieb J.

Drugs. 2018 Jun;78(8):789-798. doi: 10.1007/s40265-018-0921-7. Review.

PMID:
29790124
21.

Role of circulating tumor DNA in the management of patients with colorectal cancer.

Moati E, Taly V, Didelot A, Perkins G, Blons H, Taieb J, Laurent-Puig P, Zaanan A.

Clin Res Hepatol Gastroenterol. 2018 Oct;42(5):396-402. doi: 10.1016/j.clinre.2018.03.002. Epub 2018 Apr 5. Review.

PMID:
29627453
22.

BIABooster: Online DNA Concentration and Size Profiling with a Limit of Detection of 10 fg/μL and Application to High-Sensitivity Characterization of Circulating Cell-Free DNA.

Andriamanampisoa CL, Bancaud A, Boutonnet-Rodat A, Didelot A, Fabre J, Fina F, Garlan F, Garrigou S, Gaudy C, Ginot F, Henaff D, Laurent-Puig P, Morin A, Picot V, Saias L, Taly V, Tomasini P, Zaanan A.

Anal Chem. 2018 Mar 20;90(6):3766-3774. doi: 10.1021/acs.analchem.7b04034. Epub 2018 Mar 9.

PMID:
29498256
23.

Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).

Zaanan A, Samalin E, Aparicio T, Bouche O, Laurent-Puig P, Manfredi S, Michel P, Monterymard C, Moreau M, Rougier P, Tougeron D, Taieb J, Louvet C.

Dig Liver Dis. 2018 Apr;50(4):408-410. doi: 10.1016/j.dld.2018.01.119. Epub 2018 Mar 1.

PMID:
29409778
24.

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.

Palle J, Tougeron D, Pozet A, Soularue E, Artru P, Leroy F, Dubreuil O, Sarabi M, Williet N, Manfredi S, Martin-Babau J, Rebischung C, Abdelghani MB, Evesque L, Dreanic J, Hautefeuille V, Louafi S, Sefrioui D, Savinelli F, Mabro M, Rousseau B, Lecaille C, Bouché O, Louvet C, Lecomte T, Bonnetain F, Taieb J, Zaanan A.

Oncotarget. 2017 Sep 8;8(60):101383-101393. doi: 10.18632/oncotarget.20711. eCollection 2017 Nov 24.

25.

Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study.

Salimon M, Prieux-Klotz C, Tougeron D, Hautefeuille V, Caulet M, Gournay J, Matysiak-Budnik T, Bennouna J, Tiako Meyo M, Lecomte T, Zaanan A, Touchefeu Y.

Br J Cancer. 2018 Feb 6;118(3):325-330. doi: 10.1038/bjc.2017.413. Epub 2017 Nov 23.

26.

Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study.

Zaanan A, Palle J, Soularue E, Leroy F, Louafi S, Tougeron D, Manfredi S, Artru P, Pozet A, Taieb J.

Target Oncol. 2018 Feb;13(1):107-112. doi: 10.1007/s11523-017-0531-4.

PMID:
29090377
27.

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.

Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA.

JAMA Oncol. 2018 Mar 1;4(3):379-383. doi: 10.1001/jamaoncol.2017.2899.

28.

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).

Garlan F, Laurent-Puig P, Sefrioui D, Siauve N, Didelot A, Sarafan-Vasseur N, Michel P, Perkins G, Mulot C, Blons H, Taieb J, Di Fiore F, Taly V, Zaanan A.

Clin Cancer Res. 2017 Sep 15;23(18):5416-5425. doi: 10.1158/1078-0432.CCR-16-3155. Epub 2017 Jun 2.

29.

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.

Auclin E, Zaanan A, Vernerey D, Douard R, Gallois C, Laurent-Puig P, Bonnetain F, Taieb J.

Ann Oncol. 2017 May 1;28(5):958-968. doi: 10.1093/annonc/mdx030. Review.

30.

Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.

Taieb J, Balogoun R, Le Malicot K, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Emile JF, Mulot C, Fratté S, Levaché CB, Saban-Roche L, Thaler J, Petersen LN, Bridgewater J, Perkins G, Lepage C, Van Cutsem E, Zaanan A, Laurent-Puig P; PETACC8 Investigators.

Ann Oncol. 2017 Apr 1;28(4):824-830. doi: 10.1093/annonc/mdw687.

31.

Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study.

Mary F, Zaanan A, Boige V, Artru P, Samalin E, Coriat R, Bachet JB, Boubaya M, Benallaoua M, Tougeron D, Afchain P, Locher C, Baumgaertner I, Lecaille C, des Guetz G, Aparicio T; AGEO (Association des Gastro-Entérologues Oncologues).

Dig Liver Dis. 2016 Dec;48(12):1498-1502. doi: 10.1016/j.dld.2016.07.022. Epub 2016 Aug 9.

PMID:
27623185
32.

Small Bowel Adenocarcinoma.

Aparicio T, Zaanan A, Mary F, Afchain P, Manfredi S, Evans TR.

Gastroenterol Clin North Am. 2016 Sep;45(3):447-57. doi: 10.1016/j.gtc.2016.04.004. Review.

PMID:
27546842
33.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D.

Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.

34.

A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker.

Garrigou S, Perkins G, Garlan F, Normand C, Didelot A, Le Corre D, Peyvandi S, Mulot C, Niarra R, Aucouturier P, Chatellier G, Nizard P, Perez-Toralla K, Zonta E, Charpy C, Pujals A, Barau C, Bouché O, Emile JF, Pezet D, Bibeau F, Hutchison JB, Link DR, Zaanan A, Laurent-Puig P, Sobhani I, Taly V.

Clin Chem. 2016 Aug;62(8):1129-39. doi: 10.1373/clinchem.2015.253609. Epub 2016 Jun 1.

35.

Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.

Tougeron D, Mouillet G, Trouilloud I, Lecomte T, Coriat R, Aparicio T, Des Guetz G, Lécaille C, Artru P, Sickersen G, Cauchin E, Sefrioui D, Boussaha T, Ferru A, Matysiak-Budnik T, Silvain C, Karayan-Tapon L, Pagès JC, Vernerey D, Bonnetain F, Michel P, Taïeb J, Zaanan A.

J Natl Cancer Inst. 2016 Feb 1;108(7). doi: 10.1093/jnci/djv438. Print 2016 Jul.

PMID:
26839356
36.

Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.

Brieau B, Auzolle C, Pozet A, Tougeron D, Bouché O, Soibinet P, Coriat R, Prieux C, Lecomte T, Goujon G, Marthey L, Rougier P, Bonnetain F, Ducreux M, Taieb J, Zaanan A.

Dig Liver Dis. 2016 Apr;48(4):441-5. doi: 10.1016/j.dld.2015.12.012. Epub 2015 Dec 29.

PMID:
26775096
37.

Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.

Taieb J, Zaanan A, Le Malicot K, Julié C, Blons H, Mineur L, Bennouna J, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Lepage C, Emile JF, Laurent-Puig P.

JAMA Oncol. 2016 May 1;2(5):643-653. doi: 10.1001/jamaoncol.2015.5225.

PMID:
26768652
38.

Implications of mismatch repair-deficient status on management of early stage colorectal cancer.

Kawakami H, Zaanan A, Sinicrope FA.

J Gastrointest Oncol. 2015 Dec;6(6):676-84. doi: 10.3978/j.issn.2078-6891.2015.065. Review.

39.

Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology.

Diouf M, Filleron T, Pointet AL, Dupont-Gossard AC, Malka D, Artru P, Gauthier M, Lecomte T, Aparicio T, Thirot-Bidault A, Lobry C, Fein F, Dubreuil O, Landi B, Zaanan A, Taieb J, Bonnetain F.

Qual Life Res. 2016 Jul;25(7):1713-23. doi: 10.1007/s11136-015-1198-x. Epub 2015 Nov 28.

PMID:
26615615
40.

Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives.

Zaaimi Y, Aparicio T, Laurent-Puig P, Taieb J, Zaanan A.

Clin Res Hepatol Gastroenterol. 2016 Apr;40(2):154-60. doi: 10.1016/j.clinre.2015.09.008. Epub 2015 Nov 4. Review.

PMID:
26547136
41.

The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.

Zaanan A, Okamoto K, Kawakami H, Khazaie K, Huang S, Sinicrope FA.

J Biol Chem. 2015 Sep 25;290(39):23838-49. doi: 10.1074/jbc.M115.657833. Epub 2015 Aug 5.

42.

Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.

Brieau B, Dahan L, De Rycke Y, Boussaha T, Vasseur P, Tougeron D, Lecomte T, Coriat R, Bachet JB, Claudez P, Zaanan A, Soibinet P, Desrame J, Thirot-Bidault A, Trouilloud I, Mary F, Marthey L, Taieb J, Cacheux W, Lièvre A.

Cancer. 2015 Sep 15;121(18):3290-7. doi: 10.1002/cncr.29471. Epub 2015 Jun 5.

43.

Microsatellite instability testing and its role in the management of colorectal cancer.

Kawakami H, Zaanan A, Sinicrope FA.

Curr Treat Options Oncol. 2015 Jul;16(7):30. doi: 10.1007/s11864-015-0348-2. Review.

44.

Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial.

Anota A, Mouillet G, Trouilloud I, Dupont-Gossart AC, Artru P, Lecomte T, Zaanan A, Gauthier M, Fein F, Dubreuil O, Paget-Bailly S, Taieb J, Bonnetain F.

PLoS One. 2015 May 26;10(5):e0125350. doi: 10.1371/journal.pone.0125350. eCollection 2015.

45.

Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer risk.

Baert-Desurmont S, Charbonnier F, Houivet E, Ippolito L, Mauillon J, Bougeard M, Abadie C, Malka D, Duffour J, Desseigne F, Colas C, Pujol P, Lejeune S, Dugast C, Buecher B, Faivre L, Leroux D, Gesta P, Coupier I, Guimbaud R, Berthet P, Manouvrier S, Cauchin E, Prieur F, Laurent-Puig P, Lebrun M, Jonveaux P, Chiesa J, Caron O, Morin-Meschin ME, Polycarpe-Osaer F, Giraud S, Zaanan A, Bonnet D, Mansuy L, Bonadona V, El Chehadeh S, Duhoux F, Gauthier-Villars M, Saurin JC, Collonge-Rame MA, Brugières L, Wang Q, Bressac-de Paillerets B, Rey JM, Toulas C, Buisine MP, Bronner M, Sokolowska J, Hardouin A, Cailleux AF, Sebaoui H, Blot J, Tinat J, Benichou J, Frebourg T.

Eur J Hum Genet. 2016 Jan;24(1):99-105. doi: 10.1038/ejhg.2015.72. Epub 2015 Apr 15.

46.

Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre study.

Tougeron D, Sickersen G, Mouillet G, Zaanan A, Trouilloud I, Coriat R, Aparicio T, Des Guetz G, Lecaille C, Artru P, Cauchin E, Sefrioui D, Boussaha T, Ferru A, Matysiak-Budnik T, Silvain C, Karayan-Tapon L, Pagès JC, Vernerey D, Bonnetain F, Michel P, Taïeb J, Lecomte T; Association des Gastro-Entérologues Oncologues (AGEO).

Eur J Cancer. 2015 May;51(8):925-34. doi: 10.1016/j.ejca.2015.03.011. Epub 2015 Apr 8.

PMID:
25864037
47.

Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.

Soularue É, Cohen R, Tournigand C, Zaanan A, Louvet C, Bachet JB, Hentic O, Samalin E, Chibaudel B, de Gramont A, André T; for GERCOR.

Bull Cancer. 2015 Apr;102(4):324-31. doi: 10.1016/j.bulcan.2014.08.001. Epub 2015 Mar 3.

PMID:
25744576
48.

Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma.

Zaanan A, Park JM, Tougeron D, Huang S, Wu TT, Foster NR, Sinicrope FA.

Int J Cancer. 2015 Sep 15;137(6):1498-502. doi: 10.1002/ijc.29496. Epub 2015 Mar 9.

49.

Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.

Okamoto K, Zaanan A, Kawakami H, Huang S, Sinicrope FA.

Mol Cancer Res. 2015 Apr;13(4):659-69. doi: 10.1158/1541-7786.MCR-14-0476. Epub 2014 Dec 29.

50.

Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).

Trouilloud I, Dupont-Gossard AC, Malka D, Artru P, Gauthier M, Lecomte T, Aparicio T, Thirot-Bidault A, Lobry C, Asnacios A, Manet-Lacombe S, Fein F, Dubreuil O, Landi B, Zaanan A, Bonnetain F, Taïeb J.

Eur J Cancer. 2014 Dec;50(18):3116-24. doi: 10.1016/j.ejca.2014.09.015. Epub 2014 Oct 17.

PMID:
25454414

Supplemental Content

Loading ...
Support Center